Late last year, Netflix Chief Product Officer and Cancer Commons supporter Neil Hunt gave a talk at TEDxBeaconStreet. He believes that big data analysis outside of traditional clinical trials can help identify personalized treatments for individual patients that can significantly improve their chances of survival. As Hunt explains, Cancer Commons is an exciting embodiment of this new approach to life-saving cancer research. Watch the video:
CommonHealth, a blog affiliated with Boston’s NPR news station WBUR, recently posted an interview with Cancer Commons founder Marty Tenenbaum. Reporter Rachel Zimmerman caught up with Marty after a talk he gave at MIT in Cambridge. Marty told her his personal story, explained why Cancer Commons is collecting stories from other patients, and placed Cancer Commons’ efforts in the context of rapidly evolving understanding of the science behind cancer.
A quote from Marty: ” ‘We’re patient focused and science based; Our mission is to aggregate and analyze data, to provide patients with the best information — up-to-the-moment, personalized, and actionable to help them make informed decisions…like a Lonely Planet guide to cancer.’ ”
Every year, scientists, doctors, and representatives from pharmaceutical, diagnostics, and technology companies gather in Silicon Valley to talk shop at the Personalized Medicine World Conference (PMWC). For 2 days, they discuss the triumphs and challenges of diagnosing and treating diseases based on patients’ distinct genetic characteristics.
This year, the PMWC status quo was interrupted by a not-so-unlikely guest: the patient. Cancer Commons joined the event’s organizers to cohost a series of informative presentations for patients and advocates, delivered by doctors and researchers, as well as patients and advocates themselves. Continue reading…
Cancer Commons founder Marty Tenenbaum, PhD, recently visited Microsoft’s Richmond, CA, office to give a presentation entitled “How to Beat Cancer.”
Because of “a convergence of recent developments in genomics, big data informatics, social networks, and personalized medicine that is transforming the landscape of cancer research and treatment,” Marty says, “we are now on the threshold of being able to give each individual the knowledge, resources, and tools needed to successfully treat the one disease that matters most to them.”
Watch the complete presentation at the Microsoft Research site.
Today the journal Nature Reviews Clinical Oncology published a paper written by Cancer Commons founder Marty Tenenbaum and co-author Jeff Shrager. The piece discusses the concept of Rapid Learning Precision Oncology. In this approach, every patient receives the best available treatment for them, based on the specifics of their diagnosis. Then the outcomes (e.g., tumor shrinkage, side effects, quality of life, etc.) are used to support and refine the treatment model on which patients’ treatment decisions are based. Tenenbaum and Shrager review the Rapid Learning Precision Oncology approach and the many challenges to its implementation.
Read the article: Rapid learning for precision oncology. Nature Reviews Clinical Oncology. Jan 21, 2014. doi: 10.1038/nrclinonc.2013.244
Please contact us if you are interested in a pdf of the paper.
Today Cancer Commons and the Melanoma Research Foundation announce an online patient registry to advance research for a cure.
For Immediate Release: January 17, 2014
The Melanoma Research Foundation and Cancer Commons partner to launch online patient registry to advance research for a cure
Donate Your Data (DYD) is the first platform to collect open-access information that will be made available to patients, physicians and researchers
Washington, DC, and Palo Alto, California, January 17, 2014 – The Melanoma Research Foundation (MRF) and Cancer Commons today announce the launch of the Donate Your Data (DYD) Program, an online registry for melanoma patients and survivors. DYD encourages patients to anonymously share their cancer experiences to advance research and, in return, inform their own clinical care.
Melanoma is one of the fastest growing cancers. With a 1 in 50 lifetime risk of developing melanoma, nearly 77,000 Americans were expected to be diagnosed with the disease in 2013, resulting in over 9,400 deaths.
Through DYD, each melanoma patient records and updates personal disease characteristics in a private, secure online profile. Entries capture stage, treatments, molecular test results, side effects, and treatment responses. All data will be made freely available in de-identified form, giving doctors, researchers, and patients themselves an unprecedented resource to determine the best approaches to melanoma care, according to each patient’s unique clinical history.
“DYD aims to collect data from at least 10% of the approximately 1 million melanoma patients and survivors in the U.S., and even more worldwide,” says Shelby Moneer, Education Program Manager at the MRF. “Our partnership with Cancer Commons is an exciting new facet of our commitment to providing patient resources and supporting research into effective treatments and eventually, a cure for this disease.”
Personalized oncology is changing the cancer treatment landscape. Increasingly, patients are treated according to the distinct genetics of their tumors. To realize the full benefits of this shift, cancer patients and advocates must be engaged and informed. Cancer Commons has joined the Personalized Medicine World Conference (PMWC) to co-host a special two-day track for cancer patients and advocates. Attendees will have the opportunity to discuss personalized medicine with each other and with researchers, clinicians, and industry leaders. Distinguished speakers will present the latest advances in personalized oncology and discuss its promise for the future.
PMWC is the largest and most established global conference on personalized medicine. It provides a platform for clinical, scientific, industry, and mobile health stakeholders to collaborate and catalyze further change. Cancer patients and advocates can register for the Patient & Advocate Program (Track 4) at a discounted fee.
PMWC 2014 will take place January 27-28, 2014, at the Computer History Museum in Mountain View, CA.
Cancer Commons founder Marty Tenenbaum will lead a panel discussion at the 2014 Personalized Medicine World Conference (PMWC) on Jan 27. The discussion, entitled, “PM in Oncology Today: Making It Work for Patients, Clinicians, Researchers, and Industry,” will also feature George Demetri of Dana-Farber/Harvard Cancer Center, Vincent A. Miller of Foundation Medicine, lung cancer survivor Neil Schiffman, and Edgar Staren of CTCA Medicine and Science. Their diverse perspectives will ignite insightful discussion regarding the current use and future promise of personalized medicine in cancer.
The 6th annual PMWC conference in Silicon Valley runs Jan 27–28. It brings together leaders from multiple sectors—including business, government, healthcare-delivery, research and technology—to learn from each other and further the field of personalized medicine. Dr. Tenenbaum’s panel discussion is at 11 am on the main-stage. General registration is available through Jan 24.
Cancer Commons founder Marty Tenenbaum, PhD, will speak tomorrow at the Monte Jade Forum, an event organized by the Monte Jade Science and Technology Association (West Coast). The Forum is entitled Personalized Precision Medicine – What does it mean for the cancer patient? Dr. Tenenbaum will join oncologist Edmund Tai, MD, in a discussion of how personalized medicine, or “precision oncology,” can help cancer patients. Dr. Tenenbaum will discuss Cancer Commons as “an emerging patient-led movement that empowers each patient and their care team to get the best available knowledge for beating their cancer, and to update that knowledge in real time based on each patient’s outcome.”